Updated:
Secura Bio
Secura Bio is a biopharmaceutical company based in Mesa, United States, founded in 2019. It has secured $55 million in total funding. The company operates as...
Secura Bio
Secura Bio is a biopharmaceutical company based in Mesa, United States, founded in 2019. It has secured $55 million in total funding. The company operates as an integrated biopharmaceutical entity.
General information
Firm type
Asset Manager
Year founded
2019
Location
Region
North America
Country
United States
City
Berkeley Heights
Corporate office
Berkeley Heights, New Jersey, United States
Additional offices
Dublin, Ireland · Las Vegas, United States
Principals
Juan Estruch
Co-Founder
Chip R. Romp
Executive Vice President, US Commercial (former Seagen)
Will Brown
Chief Financial Officer
Gregory S. Wessels
Chief Commercial Officer
Christiane Langer
Senior Vice President, Global Medical Affairs
Cari Barthe
Director of People and Culture
Patrick Vink
Chairman of the Board
Jeffrey A. Ferrell
Board Member
Joerg Moeller
Board Member
Sector focus
Frequently asked questions
Who started Secura Bio and what is the background of its leadership?
The firm was co-founded in 2019 by Juan Estruch, who has over 25 years in life sciences corporate development at Novartis, Ciba-Geigy, and Genoptix. The board is chaired by Patrick Vink, former COO of Cubist, and includes Jeffrey A. Ferrell, founder of Athyrium Capital Management (per the firm's website).
How does Secura Bio differ from a traditional pharmaceutical company?
Secura Bio does not invest in early-stage drug discovery. Instead, it acquires or licenses approved or late-stage oncology therapies and applies a specialized commercial team to maximize their market potential. This operating-company model sits between a pharmaceutical company and an investment firm.
Does Secura Bio disclose its AUM or investment returns?
The firm does not publicly disclose AUM, deployment size, or portfolio returns. Its website focuses on the team's track record at prior companies rather than its own capital base (per firm website, 2025).
What types of deals does Secura Bio target?
Secura Bio targets under-exploited oncology therapies — typically marketed or late-stage assets that need repositioning or relaunch. It does not appear to participate in early-stage venture funding or public equity investments (per firm website).
Is Secura Bio structured as a family office?
Secura Bio presents itself as a commercial-stage pharmaceutical company, not a family office. Its leadership includes operating and board backgrounds from the biopharma industry. No family office affiliation is disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: